For Publishers
DiscoveryMetadataPeer reviewHostingPublishing
For Researchers
JoinPublishReviewCollect
Register
Blog
About
Search
Advanced search
My ScienceOpen
Search
For Publishers
For Researchers
Blog
About
2
views
26
references
 Top references
cited by
11
    
0 reviews
 Review
0
comments
 Comment
0
recommends
+1 Recommend
0 collections
    0
    shares
      3,708
      similar
       All similar
      • Record: found
      • Abstract: not found
      • Article: not found

      Tocilizumab treatment effectively improves coronary artery involvement in patients with Takayasu arteritis

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Related collections

          Most cited references26

          • Record: found
          • Abstract: not found
          • Article: not found

          The American College of Rheumatology 1990 criteria for the classification of takayasu arteritis

          Mary Stevens, John A Mills, Dennis Mcshane … (1990)
          Article 0 comments Cited 205 times – based on 0 reviews     Review now
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Takayasu Arteritis

            Gail S Kerr (1994)
            Article 0 comments Cited 147 times – based on 0 reviews     Review now
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Effect of a single dose of the interleukin-6 receptor antagonist tocilizumab on inflammation and troponin T release in patients with non-ST-elevation myocardial infarction: a double-blind, randomized, placebo-controlled phase 2 trial.

              Ola Kleveland, Gabor Kunszt, Marte Bratlie … (2016)
              Interleukin-6 (IL-6) contributes to atherosclerotic plaque destabilization and is involved in myocardial injury during ischaemia-reperfusion. Interleukin-6 is therefore a potential therapeutic target in myocardial infarction (MI). We hypothesized that the IL-6 receptor antagonist tocilizumab would attenuate inflammation, and secondarily reduce troponin T (TnT) release in non-ST-elevation MI (NSTEMI).
              Article 0 comments Cited 141 times – based on 0 reviews     Review now
                Bookmark
                All references

                Author and article information

                Journal
                Title: Clinical Rheumatology
                Abbreviated Title: Clin Rheumatol
                Publisher: Springer Science and Business Media LLC
                ISSN (Print): 0770-3198
                ISSN (Electronic): 1434-9949
                Publication date (Electronic): March 6 2020
                Article
                DOI: 10.1007/s10067-020-05005-7
                PubMed ID: 32144625
                SO-VID: cdbbbd64-8d33-451f-adc7-68dac59efd8e
                Copyright © © 2020
                License:

                http://www.springer.com/tdm

                History

                Data availability:

                Comments

                Comment on this article

                scite_

                Similar content3,708

                See all similar

                Cited by11

                See all cited by

                Most referenced authors570

                See all reference authors